Radionuclide-siRNA Conjugation Service
Radionuclide-siRNA conjugation is an innovative technology that integrates radioisotopes with small interfering RNAs (siRNAs) to achieve precision therapy and gene silencing through radiolabeling. Alfa Cytology's research in this area is focused on developing radioisotope-conjugated siRNA molecules for targeted therapies against tumors and other diseases.
Introduction to Radionuclide-siRNA Conjugation
Radionuclide-siRNA conjugation is a cutting-edge technology combining radioisotopes with small interfering RNA (siRNA) molecules. Radioisotopes enable imaging and therapy, while siRNAs inhibit target genes via RNA interference. This combination allows precise targeted therapy and real-time monitoring through radiolabeling. In this approach, the radioisotope chemically bonds to the siRNA, ensuring stable delivery to disease sites. Particularly in cancer treatment, siRNAs effectively suppress specific tumor genes, reducing tumor growth and enhancing other treatments' efficacy.
Fig.1 Radiolabeling of functional oligonucleotides and its molecular imaging applications. LIU D, et al., 2022)
Radionuclide-siRNA Conjugation Development Methods
In this method, the radionuclide is chemically bonded directly to the siRNA molecule using reactive groups such as amino, sulfhydryl, or carboxyl groups.
- Indirect Carrier Conjugation
This technique uses an intermediate carrier-such as a polymer, nanoparticle, or antibody-as a bridge. The radionuclide is first attached to the carrier, which is then physically or chemically linked to the siRNA.
- Nanoparticle Surface Modification
Nanoparticles (e.g., gold or lipid nanoparticles) are surface-modified with radionuclides. The siRNA molecules are then attached to these surfaces through electrostatic or covalent bonds.
- Biorecognition Ligand Conjugation
Radionuclides are linked to biorecognition molecules, like antibodies or receptor ligands, which then interact with the siRNA, enabling targeted binding.
A crosslinker, with multiple reactive sites, is employed to covalently attach the radionuclide to the siRNA, forming a stable complex.
- Nucleic Acid Aptamer Ligation
Nucleic acid aptamers bind to both radionuclides and siRNA molecules, forming stable complexes. This specific binding improves targeting and cellular uptake of the radiolabel.
Our Services
Leveraging its advanced technology platform and extensive R&D expertise, Alfa Cytology combines radioisotopes with small interfering RNAs (siRNAs) to develop precision-targeted therapeutic programs. Through innovative research in radiopharmaceuticals and gene therapy, Alfa Cytology is pioneering the application of radionuclide-siRNA conjugation technology, offering novel approaches to enhance the effectiveness of radiation therapy.
Radionuclide Generation and Screening Service
Alfa Cytology provides a diverse selection of radionuclides that can be precisely conjugated and labeled with siRNA. This combination not only boosts the effectiveness of targeted therapy but also facilitates real-time monitoring of the treatment process through radiographic imaging.
Preclinical Services for Radionuclide-siRNA Conjugation
In addition to offering an extensive array of siRNA labeling services, Alfa Cytology provides a comprehensive suite of preclinical research services for radionuclide-siRNA conjugation. Our expertise enables tailored solutions for optimizing conjugation strategies, ensuring enhanced efficacy and safety.
Leveraging extensive R&D experience and a multidisciplinary team of experts, Alfa Cytology offers comprehensive, one-stop development services for radionuclide-siRNA conjugation. We are dedicated to providing our clients with robust technical support, ensuring projects progress smoothly from initial development to final application. For any inquiries about our services, please feel free to contact us; we're happy to assist and address your questions.
Reference
- LIU D, XIA Q, DING D, et al. Radiolabeling of functional oligonucleotides for molecular imaging [J]. Frontiers in bioengineering and biotechnology, 2022, 10: 986412.
For research use only. Not intended for any clinical use.
Related Service
